CytoDyn (CYDY) Net Income towards Common Stockholders (2010 - 2026)
CytoDyn (CYDY) posted Net Income towards Common Stockholders of -$4.7 million for Q1 2026, up 79.25% on a QoQ basis from -$22.6 million in Q4 2025, and up 1.43% year-over-year from -$4.6 million in Q1 2025.
CytoDyn (CYDY) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
CytoDyn's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$4.7 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 1.43% year-over-year to -$4.7 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$38.8 million (down 447.46% YoY) and the FY2025 annual result came in at $3.7 million, up 107.51% from the prior year.
- Net Income towards Common Stockholders was -$4.7 million for Q1 2026 at CytoDyn, up from -$22.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $19.2 million in Q3 2024 and bottomed at -$84.1 million in Q2 2022.
- A 5-year average of -$16.7 million and a median of -$11.9 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders jumped 266.17% — and 2025, when it slumped 374.14%.
- CytoDyn's Net Income towards Common Stockholders stood at -$26.5 million in 2022, then surged by 63.91% to -$9.6 million in 2023, then surged by 50.14% to -$4.8 million in 2024, then tumbled by 374.14% to -$22.6 million in 2025, then soared by 79.25% to -$4.7 million in 2026.
- Business Quant data shows CYDY's Net Income towards Common Stockholders at -$4.7 million in Q1 2026, -$22.6 million in Q4 2025, and -$5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | -0.68 |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - | -453.82 Mn |
| 10 | CytoDyn | 258.22 Mn | 258.22 Mn | - | -4.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -4.69 Mn |
| Nov 30, 2025 | -22.61 Mn |
| Aug 31, 2025 | -5.54 Mn |
| May 31, 2025 | -5.96 Mn |
| Feb 28, 2025 | -4.76 Mn |
| Nov 30, 2024 | -4.77 Mn |
| Aug 31, 2024 | 19.23 Mn |
| May 31, 2024 | -16.79 Mn |
| Feb 29, 2024 | -11.92 Mn |
| Nov 30, 2023 | -9.56 Mn |
| Aug 31, 2023 | -11.57 Mn |
| May 31, 2023 | -18.61 Mn |
| Feb 28, 2023 | -13.70 Mn |
| Nov 30, 2022 | -26.50 Mn |
| Aug 31, 2022 | -20.99 Mn |
| May 31, 2022 | -84.12 Mn |
| Feb 28, 2022 | -41.29 Mn |
| Nov 30, 2021 | -40.08 Mn |
| Aug 31, 2021 | -45.34 Mn |
| May 31, 2021 | -70.07 Mn |